Refine by
Biologic Therapeutic Articles & Analysis
41 news found
He has held leadership and senior roles at Novartis, GE Healthcare, Quest Diagnostics, Tethys Bioscience and the US Department of Energy. About Juvena Therapeutics Juvena Therapeutics is a biotech company accelerating the development of regenerative therapeutics by unlocking the therapeutic potential of secreted proteins. ...
Eikonoklastes Therapeutics, a preclinical biotech company developing treatments for today’s most challenging diseases, and Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced a manufacturing partnership that will advance Eikonoklastes’ AAV-based gene therapy, ET-101, into clinical trials for the ...
Further to the announcement of the exclusive option to license the CORE-NK platform released on 21 November 2022, at the request of the ASX, Chimeric Therapeutics (ASX: CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, provides additional information regarding an exclusive license agreement with Case Western Reserve ...
BNCT has the potential to deliver highly effective, cell-localized radiation therapy to treat tumors with minimal impact on the patient's quality of life compared to other available treatment options, such as radiation, chemotherapy or biological treatment modalities. Neutron Therapeutics, Inc. and the Helsinki University Hospital are collaborating to launch the ...
Secreted proteins are a proven class of biologics with tremendous therapeutic potential, as they regulate tissue repair and regeneration, organ development, and immune response to disease. ...
Ray Therapeutics, a biotechnology company developing optogenetic gene therapies for patients with retinal degenerative conditions, and Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced further collaboration for their manufacturing partnership to include clinical stage plasmid DNA production to support Ray ...
With this partnership dynamic, pharmaceutical companies and research organizations using SilcsBio’s computer-aided drug design services will be able to tap into Helix BioStructure’s 3-D structures of proteins (or other biological targets). This, in turn, enables pharmaceutical researchers a seamless way to confirm the mechanism and engagement of the target, enabling ...
MOBILion’s separations technology provides higher resolution, faster analysis and simpler workflows to reveal molecules that are most important in characterizing biologic therapeutics, discovering biomarkers, and improving the accuracy of diagnostic tests. ...
Kallyope, Inc., a leading biotechnology company focused on identifying and developing therapeutics involving the gut-brain axis, today announced the promotion of Shirly Pinto, Ph.D., to Chief Scientific Officer and the appointments of Jiajun Liu, Ph.D., as Vice President and Head of Biometrics and Michael Crutchlow, M.D., as Vice President and Head of Translational Medicine. ...
Iktos, a company specialized in Artificial Intelligence (AI) for new drug design and Sygnature Discovery, a leading integrated drug discovery CRO headquartered in Nottingham, UK, with expertise across a range of therapeutic and biological target classes today announced a collaboration agreement in AI for new drug design. ...
ByIktos
In life science research, methods like LC and LC-MS are usually used to measure therapeutic biological molecules. In order to make the LC and LC-MS systems fulfill their mission, specific standards and reagents are needed. ...
“We’re delighted to welcome Elaine to our growing team, as we realize our mission of bringing forth the next generation of CRISPR-based diagnostics and therapeutics,” said Trevor Martin, co-founder and Chief Executive Officer of Mammoth Biosciences. ...
In addition, this technology is being designed to identify an overall biologic cancer signature to guide therapeutic management from as early as pre-treatment biopsy/resection specimens. ...
Terray Therapeutics, a biotechnology company propelling drug discovery into the information age, today announced the appointments of Feroze (Fez) Ujjainwalla, PhD, as Head of Business, and Adam D. ...
Food and Drug Administration (FDA) and will be regulated as a drug-biologic through a therapeutics biologics license application (BLA). Importantly, DiscGenics announced in August 2019 that the FDA granted Fast Track designation for IDCT as a potential treatment option for chronic low back pain. ...
Rani Therapeutics has developed an oral biologics device, named RaniPill HC, for the delivery of biologics. The new device is capable of delivering a drug payload of up to or more than 500% higher compared to the company’s current oral biologics capsule. A preclinical study of RaniPill HC has been conducted by the ...
In addition, this technology is being designed to identify an overall biologic cancer signature to guide therapeutic management from as early as pre-treatment biopsy/resection specimens. ...
Speaking at the American Academy of Optometry 2021 annual meeting in Boston, Anthony DeWilde, OD, FAAO, discussed biologics, which hold promise for the treatment of ophthalmic diseases. ...
Ghent, Belgium – November 30, 2021 – Confo Therapeutics today announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals, Inc. whereby Confo’s technology platform, which uses conformationally selective VHH antibodies – ConfoBodies® – to stabilize GPCRs (G protein-coupled receptors) in disease-relevant ...
The primary endpoints of these trials include safety and feasibility. Secondary endpoints include biological activity of the therapeutic vaccine TG4050. CELLULAR IMMUNE RESPONSE WAS EVALUABLE FOR 4 OF THE PATIENTS TREATED WITH TG4050. ...